Free tool
FAERS Monitor: Qudexy Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205122 or its brand name (Qudexy Xr, Topiramate). Reports on generic versions are filed under their own applications.
Reports
50,790
Serious
38,762
76% of reports
Hospitalization
14,435
Death reported
5,657
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7,062
- off label use5,701
- headache3,701
- nausea3,349
- fatigue3,211
- product use in unapproved indication2,627
- pain2,577
- migraine2,555
- dizziness2,442
- seizure2,293
- diarrhoea2,219
- condition aggravated2,216
- vomiting2,196
- drug intolerance2,143
- depression1,977
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 139 |
| 2005 | 254 |
| 2006 | 207 |
| 2007 | 196 |
| 2008 | 383 |
| 2009 | 775 |
| 2010 | 941 |
| 2011 | 1,213 |
| 2012 | 1,395 |
| 2013 | 1,214 |
| 2014 | 1,551 |
| 2015 | 2,440 |
| 2016 | 2,976 |
| 2017 | 2,710 |
| 2018 | 3,587 |
| 2019 | 3,999 |
| 2020 | 3,696 |
| 2021 | 3,734 |
| 2022 | 3,599 |
| 2023 | 3,912 |
| 2024 | 4,566 |
| 2025 | 4,472 |
| 2026 | 2,826 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,369 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 2,555 | 11.4 | 10.9 | 23,593 |
| drug intoleranceSignal | 2,143 | 9.4 | 9.0 | 15,736 |
| seizureSignal | 2,293 | 8.4 | 8.0 | 14,652 |
| product use in unapproved indicationSignal | 2,627 | 4.4 | 4.3 | 6,971 |
| depressionSignal | 1,977 | 3.6 | 3.5 | 3,756 |
| condition aggravatedSignal | 2,216 | 3.0 | 2.9 | 3,040 |
| off label useSignal | 5,701 | 2.7 | 2.6 | 6,361 |
| headacheSignal | 3,701 | 2.5 | 2.4 | 3,263 |
| drug ineffectiveSignal | 7,062 | 2.2 | 2.2 | 5,056 |
| dizzinessSignal | 2,442 | 2.0 | 2.0 | 1,305 |
| vomiting | 2,196 | 1.9 | 1.9 | 1,015 |
| nausea | 3,349 | 1.8 | 1.7 | 1,126 |
| pain | 2,577 | 1.7 | 1.7 | 832 |
| fatigue | 3,211 | 1.7 | 1.7 | 980 |
| diarrhoea | 2,219 | 1.4 | 1.4 | 289 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.